Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

This study has been completed.
Sponsor:
Collaborator:
Janssen-Cilag Ltd.
Information provided by:
Nordic Myeloma Study Group
ClinicalTrials.gov Identifier:
NCT00417911
First received: January 3, 2007
Last updated: June 17, 2010
Last verified: June 2010